|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's range||83.77 - 84.69|
|52-week range||24.55 - 87.65|
|PE ratio (TTM)||11.79|
|Earnings date||2 Nov 2017|
|Dividend & yield||3.30 (3.40%)|
|1y target est||86.83|
In 2Q17, Sanofi’s (SNY) vaccine business reported revenues of 1.0 billion euros, which is a YoY rise of 26.2% on a CER basis and 19.2% on a CER and CS basis.
Launched in US markets in June 2017, Kevzara (sarilumab), Sanofi (SNY) and Regeneron’s (REGN) IL-6 receptor antibody, has received favorable feedback from the physician community.
Regeneron became a star with its treatment for a common eye disease, but treatments for dermatitis, arthritis, asthma and cancer could bring superstardom.
Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).
Warp Drive Bio Inc. could wind up $387 million richer thanks to a new antibiotic drug deal struck with Roche.
In 2Q17, Sanofi’s (SNY) Sanofi Genzyme, its specialty care business, reported revenues of 1.7 billion euros, which is a 13.6% rise YoY (year-over-year).
Of the three analysts covering Sanofi in October 2017, two have rated the stock a “strong buy,” and one has rated it a “hold.”
“They were asking for help to get the drug back. They were dying. Most of them died. It was very motivating to try to get it back."
VAL-DE-REUIL, France, Oct (Shenzhen: 000069.SZ - news) 12 (Reuters) - Sanofi (LSE: 0O59.L - news) on Thursday expressed confidence in the growth of its influenza vaccines after committing to invest 170 million euros to expand its manufacturing facility at Val-de-Reuil in north-western France. The new facility will allow Sanofi Pasteur, the group's vaccines arm, to expand the supply of VaxigripTetra, its newest "quadrivalent" vaccine, to up to 70 countries from around 20 currently. VaxigripTetra protects against four strains of the flu virus and competes with other quadrivalent and "trivalent" products already on the market.
Sanofi will invest 170 million euros to expand its vaccines manufacturing site at Val-de-Reuil in north-western France, in a drive aimed at boosting the production of one of its influenza vaccines. The ...
Sanofi invests €170 million in new vaccine production facility in France - Expansion at Val de Reuil reinforces the company`s position as a global leader in seasonal flu vaccines - Paris, France - October ...
With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.
AnaptysBio soared Tuesday after its eczema drug appeared to outperform a potential blockbuster rival drug from Regeneron and Sanofi.
Emergent BioSolutions (EBS) announced that it has acquired FDA-licensed smallpox vaccine's business of Sanofi (SNY) ??? ACAM2000.
Amgen's patents covering LDL cholesterol-lowering drug Repatha are likely to be invalidated, an analyst says.
Regeneron Pharmaceuticals(REGN) and partner Sanofi, Inc. (SNY) receives a favorable ruling from the Court of Appeals for the Federal Circuit relating to Praluent.
French pharmaceutical group Sanofi (SASY.PA) is set to start the process to sell its generic drug business in Europe, and at least six funds have expressed interest to investment banks mandated by group, France's Le Figaro newspaper reported. Rothschild and JP Morgan, two investment banks mandated by Sanofi to handle the divestment, will send out memos to potential buyers in the next few weeks, Le Figaro said in its Friday edition. Sources told Reuters in March that Rothschild [ROT.UL], JP Morgan (JPM.N) and Morgan Stanley (MS.N) had been asked to organise the long-awaited deal.
French pharmaceutical group Sanofi is set to start the process to sell its generic drug business in Europe, and at least six funds have expressed interest to investment banks mandated by group, France's ...
A U.S. federal appeals court said Regeneron Pharmaceuticals and partner Sanofi can continue selling their cholesterol drug, dealing a blow to rival Amgen, which had accused the companies of violating its ...
British drugs company BTG Plc said on Thursday it will buy U.S.-based cardiovascular catheter maker Roxwood Medical for up to $80 million. The deal, which is expected to be accretive to adjusted profit ...
LONDON, Oct (Shenzhen: 000069.SZ - news) 3 (Reuters) - A seasonal flu vaccine that would be the first in the world to fight all types of the virus is to be tested in a two-year clinical trial involving more than 2,000 patients by researchers in Oxford. The so-called universal vaccine was developed by Oxford University's Jenner Institute and Vaccitech, a spin-out biotech company founded by Jenner scientists. Current flu vaccines have to be changed each year to match strains of virus circulating at the time and they do not always protect people that well, especially older patients with weak immune systems.
LONDON/MILAN, Sept 22 (Reuters) - European shares steadied on Friday, as tensions over North Korea kept some investors on the sidelines ahead of a national election in Germany that conservative Chancellor Angela Merkel looks set to win. French cosmetics giant L'Oreal was a notable gainer on speculation about ownership changes, rising as much as 6.7 percent after billionaire Liliane Bettencourt, whose family founded the firm and still owns the largest stake in it, died.
European shares fell in early deals on Friday on fresh tension on the North Korean front, while L'Oreal rallied in Paris on talk about possible ownership changes at the cosmetics giant. L'Oreal rose more ...
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy, met its primary efficacy endpoint and all secondary endpoints. The primary endpoint for the study was the change from baseline in the modified neuropathy impairment score (mNIS+7) at 18 months.